Baird Adjusts Price Target on IQVIA Holdings to $159 From $161, Maintains Neutral Rating

Published on 17/06/2025 at 11:19

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Iqvia Holdings Inc.

Evercore ISI Adjusts Price Target on IQVIA to $180 From $170, Maintains Outperform Rating	07-09	MT
Leerink Partners Adjusts Price Target on IQVIA Holdings to $200 From $210, Maintains Outperform Rating	07-08	MT
IQVIA Holdings Inc.(NYSE:IQV) dropped from Russell Midcap Growth Index	06-30	CI
IQVIA Holdings Inc.(NYSE:IQV) dropped from Russell 3000 Growth Index	06-30	CI
IQVIA Holdings Inc.(NYSE:IQV) dropped from Russell 1000 Growth Index	06-30	CI
IQVIA Holdings Inc.(NYSE:IQV) dropped from Russell 3000E Growth Index	06-30	CI
IQVIA Holdings Inc.(NYSE:IQV) dropped from Russell 3000E Growth Benchmark	06-29	CI
IQVIA Holdings Inc.(NYSE:IQV) dropped from Russell 3000 Growth Benchmark	06-29	CI
IQVIA Holdings Inc.(NYSE:IQV) dropped from Russell Midcap Growth Benchmark	06-29	CI
IQVIA Holdings Inc.(NYSE:IQV) dropped from Russell 1000 Growth Benchmark	06-29	CI
IQVIA Holdings Inc. - Special Call	06-23
Baird Adjusts Price Target on IQVIA Holdings to $159 From $161, Maintains Neutral Rating	06-17	MT
IQVIA Launches New AI Agents for Life Sciences and Healthcare	06-11	CI
IQVIA Prices $2 Billion Senior Notes Due 2032	06-02	MT
IQVIA Announces Pricing Of Senior Notes	06-02	RE
Iqvia Plans $2 Billion Notes Offering	06-02	MT
Iqvia Announces Offering Of Senior Notes	06-02	RE
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Rifaximin Tablets, 550 Mg	06-02	CI
Claritev Corporation Appoints Mohamed Ramzy as SVP and General Manager, International	05-28	CI
Rein Therapeutics Announces First Patient Dosed In Renew Phase 2 Trial Of Lti-03 In Patients With Ipf	05-27	RE
IQVIA Holdings Inc. Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients with Ipf	05-27	CI
Trump's Tariff Blitz Roils Markets, Targets EU and Apple	05-23
Redburn Atlantic Adjusts Price Target on IQVIA Holdings to $188 From $255, Maintains Buy Rating	05-23	MT
Analyst recommendations: Crowdstrike, AMD, Boeing, Intuit, Okta…	05-23
IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials	05-16	CI